These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

158 related items for PubMed ID: 1553903

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced epithelial carcinoma of the ovary: a Gynecologic Oncology Group study.
    McGuire WP, Blessing JA, Berman ML.
    Invest New Drugs; 1989 Nov; 7(4):333-6. PubMed ID: 2557300
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Phase II evaluation of esorubicin (4'deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study.
    Vaughn CB, Salmon SE, Fleming TR.
    Invest New Drugs; 1990 Feb; 8(1):81-5. PubMed ID: 2188929
    [Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. Clinical cardiotoxicity of esorubicin (4'-deoxydoxorubicin,DxDx): prospective studies with serial gated heart scans and reports of selected cases. A Cancer and Leukemia Group B report.
    Ringenberg QS, Propert KJ, Muss HB, Weiss RB, Schilsky RL, Modeas C, Perry MC, Norton L, Green M.
    Invest New Drugs; 1990 May; 8(2):221-6. PubMed ID: 2166722
    [Abstract] [Full Text] [Related]

  • 9. Phase II study of esorubicin (4'-deoxydoxorubicin) in advanced or metastatic squamous carcinoma of the uterine cervix: a Gynecologic Oncology Group Study.
    McGuire WP, Blessing JA, Yordan E, Beecham J.
    Invest New Drugs; 1989 Jul; 7(2-3):235-8. PubMed ID: 2793379
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Phase II study of esorubicin (4'deoxydoxorubicin) in anthracycline naive patients with ovarian cancer.
    Green MD, Speyer JL, Wernz JC, Colombo N, Beller U, Muggia FM, Beckman EM.
    Invest New Drugs; 1990 Aug; 8(3):333-6. PubMed ID: 2272774
    [Abstract] [Full Text] [Related]

  • 12. Esorubicin in advanced ovarian epithelial cancer. A phase II study of the EORTC Gynecological Cancer Cooperative Group.
    van Oosterom AT, Aapro MS, Carnino F, van der Burg ME, Pecorelli S, Rotmensz N, Dalesio O, Vermorken JB.
    Eur J Cancer Clin Oncol; 1988 Aug; 24(8):1379-80. PubMed ID: 3181261
    [No Abstract] [Full Text] [Related]

  • 13. Esorubicin (deoxydoxorubicin) has low grade activity in malignant melanoma. Results of an Eastern Cooperative Oncology Group study (EST 2685).
    Hochster H, Hunt M, Green M, Parkinson D, Smith T.
    Invest New Drugs; 1990 Aug; 8(3):329-32. PubMed ID: 2272773
    [Abstract] [Full Text] [Related]

  • 14. Phase II trial of 4'-0-tetrahydropyranyladriamycin (pirarubicin) in head and neck carcinoma.
    Sridhar KS, Hussein AM, Benedetto P, Ardalan B, Savaraj N, Richman SP.
    Cancer; 1992 Sep 15; 70(6):1591-7. PubMed ID: 1516010
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.